Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00780507 · ClinicalTrials.gov registry record

Fecal Biomarker Study for Patients With Ulcerative Colitis

A clinical trial of Ulcerative Colitis, sponsored by Warner Chilcott.

Completed
Registry status
89
Enrollment target
20
Study locations

NCT00780507: Completed study of Ulcerative Colitis, sponsored by Warner Chilcott.

NCT00780507 is a study of Ulcerative Colitis that has completed, run by Warner Chilcott. The registered enrollment target is 89 participants, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00780507, a study of Ulcerative Colitis, has completed, sponsored by Warner Chilcott.

COMPLETED
Registry status
89 participants
Enrollment target
20
Study locations

Study Summary

The present study will analyze fecal levels of FC and FL in UC patients who relapse (flare) while on a QD or a BID Asacol treatment regimen and compare those levels to levels of FC and FL in UC patients who do not relapse (flare).

Conditions Studied

Study Locations (20)

California

  • Research Facility - Anaheim
  • Research Facility - Folsom
  • Research Facility - Los Angeles
  • Research Facility - Merced
  • Research Facility - San Diego
  • Research Facility - Upland

Florida

  • Research Facility - Fort Lauderdale
  • Research Facility - New Port Richey
  • Research Facility - Palm Harbor
  • Research Facility - Tampa
  • Research Facility - Zephyrhills

Georgia

  • Research Facility - Decatur
  • Research Facility - Marietta
  • Research Facility - Newnan

Illinois

  • Research Facility - Arlington Heights
  • Research Facility - Oak Lawn
  • Research Facility - Urbana

Arkansas

  • Research Facility - Lowell

Colorado

  • Research Facility - Lafayette

Connecticut

  • Research Facility - Torrington

Trial Details

FieldValue
Enrollment Target 89 participants
Start Date 2007-08
Est. Completion 2009-07
Warner Chilcott

53 total trials

What the finished NCT00780507 record still lists

NCT00780507 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 89 participants, a relatively small participant target, below the 2,057-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 0 interventions.

NCT00780507 names 20 study sites across 7 states, led by California, Florida, Georgia.

Frequently Asked Questions

What is clinical trial NCT00780507 about?

NCT00780507 is a clinical study titled "Fecal Biomarker Study for Patients With Ulcerative Colitis". The present study will analyze fecal levels of FC and FL in UC patients who relapse (flare) while on a QD or a BID Asacol treatment regimen and compare those levels to levels of FC and FL in UC patients who do not relapse (flare).

What is the current status of trial NCT00780507?

This trial is currently completed. The enrollment target is 89 participants. The study started on 2007-08. Estimated completion is 2009-07.

What conditions does trial NCT00780507 study?

This clinical trial studies the following conditions: Ulcerative Colitis.

Who is sponsoring clinical trial NCT00780507?

This trial is sponsored by Warner Chilcott, which has 53 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00780507 being conducted?

This trial has 20 study locations across Arkansas, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Ulcerative Colitis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00780507's enrollment target sits among peer trials

89 70th of 122 higher than 53 of 122 other Ulcerative Colitis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03682289 · 89 participants · Phase 2

    Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors

  • NCT04787939 · 89 participants · NA

    Early Feeding After Oral Cavity Reconstruction

  • NCT05480449 · 89 participants · Phase 1

    Autologous HuCART19 T Cells Manufactured Using the CliniMACS Prodigy Platform for Pediatric B-ALL (huCART19 Prodigy)

  • NCT05604131 · 89 participants · Phase 2

    Cardiac MRI-guided Deferiprone Therapy for Acute Myocardial Infarction Patients

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00780507, the US trial registry maintained by the National Library of Medicine. NCT00780507 (small enrollment · wide site footprint · completed) retrieved and formatted by PlainTrial, see methodology.